This #InternationalWomensDay, we celebrate all the remarkable women who drive innovation and excellence in our global community. As we #AccelerateAction at Blueprint Medicines, we remain committed to dismantling barriers and creating pathways for women to thrive, which has been part of our story since our founding. From boardrooms to laboratories, we will continue cultivating female leaders to help build a more equitable future. #IWD2025
Blueprint Medicines
生物技术研究
Cambridge，Massachusetts 58,091 位关注者
Striving to improve and extend patients' lives
关于我们
Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a proven track record of success with two approved medicines in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including systemic mastocytosis and chronic urticaria, breast cancer and other solid tumors. Patients are at the center of our mission. We know that in order to make a difference in their lives, we must create an environment where our employees — also known as the Blue Crew — can do their best work. Our culture of transparency, curiosity and diversity empowers us to draw upon a wide range of backgrounds and perspectives to build a conscientious team dynamic. Ideas come from every member of the Blue Crew, from the executive team to new hires. Each day, our teams commit to approach one another with respect and trust: a simple promise that fosters an inclusive and collaborative spirit. We care deeply about the communities where we live and work, and we strive to make a profound impact where it matters most. Learn more about who we are and explore our career opportunities at https://www.blueprintmedicines.com/careers/. Read our community guidelines: https://www.blueprintmedicines.com/community-guidelines/.
- 网站
-
https://www.blueprintmedicines.com
Blueprint Medicines的外部链接
- 所属行业
- 生物技术研究
- 规模
- 501-1,000 人
- 总部
- Cambridge，Massachusetts
- 类型
- 上市公司
- 创立
- 2011
- 领域
- targeted therapy、systemic mastocytosis、breast cancer、allergy/inflammatory、hematology/oncology、solid tumors、drug design和mast cell biology
地点
Blueprint Medicines员工
动态
-
We're proud to celebrate #BlueCrew Appreciation Day and recognize our incredible team, who bring passion and determination to our goal of making a meaningful impact on patients' lives. As we continue driving excellence and innovation across our business, we recognize the importance of supporting overall well-being to help each person thrive personally and professionally. We're immensely grateful for our Blue Crew, today and every day. #ThankYouTeam
-
Systemic mastocytosis (SM) often presents with skin symptoms, making dermatologists key partners in early diagnosis and multidisciplinary care. At the 2025 MEDICAL DERMATOLOGY SOCIETY / American Academy of Dermatology Annual Meetings, we’re looking forward to engaging with the dermatology community to deepen our understanding of SM, support diagnostic efforts and explore the real-world patient journey. At #AAD2025, we're hosting a non-CME educational program to dive into the role of a dermatologist in recognizing and diagnosing SM. If you're a healthcare professional, join our event to learn more.
-
We leave another year at #AAAAI25 feeling energized and inspired by the connections, insights and industry innovations. During the conference, we shared our latest research on systemic mastocytosis and our progress expanding into other mast cell disorders. Thank you to everyone who joined us throughout the meeting!
-
-
In our efforts to truly understand the experiences of people living with indolent systemic #mastocytosis (ISM), we work with partners to collect and analyze real-world data that inform our ability to improve and extend patients’ lives. At #AAAAI25 today, we're presenting findings from a study in partnership Dr. Thanai Pongdee to evaluate the real-world disease burden and natural history of ISM. This study involves the analysis of de-identified electronic health record data from the Mayo Clinic Platform via the nference Analytics Platform. Learn more below:
-
On #RareDiseaseDay, we're honoring the strength and resilience of the systemic mastocytosis (SM) community. As we continue investing in research to understand the disease burden and strive to improve outcomes, SM’s impact on patients’ bone health is becoming increasingly clear. At the 2025 AAAAI / WAO Joint Congress, we’re sharing findings that highlight the prevalence of low bone density in people living with indolent systemic mastocytosis (ISM), reflecting another step toward our goal of helping patients live fuller lives. Learn more in our latest blog: https://lnkd.in/eHytJ_ky #AAAAI25
-
At #AAAAI25, we're presenting a breadth of data reflecting our ongoing efforts to innovate the treatment of mast cell-driven diseases and address urgent patient needs. Across 14 presentations, we’re sharing three-year median follow-up data from our PIONEER trial in indolent systemic mastocytosis (ISM), real-world evidence characterizing the burden of SM, Phase 1 healthy volunteer study results for our wild-type KIT inhibitor, and more. Read our press release: https://lnkd.in/eCE5PPk4
-
-
Mast cells play a crucial role in inflammatory responses for many disorders. When activated, they can trigger a range of severe symptoms across organ systems. Leveraging our deep understanding of mast cell biology, we aim to expand our research into a broad array of allergic and inflammatory diseases. Join us at #AAAAI25 to learn more.
-
At #AAAAI25, we look forward to sharing a range of presentations highlighting our leadership in mast cell disorders and unparalleled understanding of the disease biology. Join the #BlueCrew at Booth 1141 to discuss a breadth of research in systemic mastocytosis as well as Phase 1 healthy volunteer study results for our wild-type KIT inhibitor, which lay the foundation for our?clinical proof-of-concept program.
-
Mast cells play a core role in the biology of many allergic and inflammatory disorders including systemic mastocytosis (SM), a disease characterized by often debilitating and unpredictable symptoms. At the AAAAI/WAO Joint Congress, we're hosting an educational program with allergy and immunology experts Dr. Matthew Giannetti and Dr. Andrew White, where we'll discuss mast cells and their role in driving SM and other diseases. If you're attending #AAAAI25, be sure to join us.
-